IP Library › Granted Patent US 10,898,737
Granted Patent B2
US 10,898,737 · App. 16/410,463 · Granted Jan 26, 2021

Substituted piperidine compound and use thereof

Inventors: Tatsuhiko Fujimoto (Kanagawa, JP); Kentaro Rikimaru (Kanagawa, JP); Hiromichi Sugimoto (Tokyo, JP); Takahiro Matsumoto (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
A61P25/00C07D211/24C07D211/36C07D211/56C07D215/44C07D401/06C07D401/12C07D401/14C07D405/06C07D405/12C07D405/14C07D409/06C07D409/12C07D413/06C07D417/06C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,737
App. No.
16/410,463
Granted
Jan 26, 2021
Kind
B2
Abstract

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

Claims (1)

1. A pharmaceutical composition comprising methyl (2R,3S)-3-((methyl sulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof.

Priority Claims (1)
JP 2016-019834 · Feb 4, 2016 · national
Continuity (2)
Division 15421702 · Feb 1, 2017
Related Publication 20190263843A1 · Aug 29, 2019
Cited By (5)
US 12,281,073 US 12,441,710 US 12,534,471 US 12,594,269 US 12,637,476